PROTECTIVE EFFECTS OF ANGIOTENSIN II BLOCKADE WITH OLMESARTAN MEDOXOMIL ON RESISTANCE VESSEL REMODELING

PROTECTIVE EFFECTS OF ANGIOTENSIN II BLOCKADE WITH OLMESARTAN MEDOXOMIL ON RESISTANCE VESSEL REMODELING

The VIOS (Vascular Improvement with Olmesartan medoxomil Study) study is a randomized, parallel study to determine the relative effects of suppressing the renin-angiotensin system (RAS) with the angiotensin receptor antagonist olmesartan medoxomil versus suppressing sympathetic drive with the beta-a...

Full description

Bibliographic Details
Main Authors:	Ronald D. Smith, Hiroshi Yokoyama, David B. Averill, Lori Cooke, K. Bridget Brosnihan, Ernesto L. Schiffrin, Carlos M. Ferrario
Format:	Article
Language:	Russian
Published:	«FIRMA «SILICEA» LLC 2010-10-01
Series:	Российский кардиологический журнал
Online Access:	https://russjcardiol.elpub.ru/jour/article/view/1500

Similar Items

EFFECT OF ANGIOTENSIN RECEPTOR BLOCKADE ON ENDOTHELIAL FUNCTION: FOCUS ON OLMESARTAN MEDOXOMIL
by: C. Ferrario
Published: (2010-12-01)

Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil
by: Carlos Ferrario
Published: (2009-03-01)

Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension
by: Mark Greathouse
Published: (2006-12-01)

Olmesartan Medoxomil, An Angiotensin II-Receptor Blocker, Ameliorates Renal Injury In db/db Mice
by: Zhu Y, et al.
Published: (2019-10-01)

EVALUATION OF ANTIHYPERTENSIVE THERAPY WITH THE COMBINATION OF OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
by: Steven G. Chrysant, et al.
Published: (2011-06-01)

Olmesartan medoxomil: current status of its use in monotherapy
by: Hans R Brunner
Published: (2006-12-01)

Synthesis of related substances of olmesartan medoxomil, an anti-hypertensive drug
by: Karrothu S. Babu, et al.
Published: (2010-05-01)

Reversal of vascular hypertrophy in hypertensive patients through blockade of angiotensin II receptors
by: R. D. Smith, et al.
Published: (2010-12-01)

The blocking of angiotensin II type 1 receptor and RhoA/Rho kinase activity in hypertensive patients: Effect of olmesartan medoxomil and implication with cardiovascular-renal remodeling
by: Verdiana Ravarotto, et al.
Published: (2015-12-01)

Design of Olmesartan Medoxomil-Loaded Nanosponges for Hypertension and Lung Cancer Treatments
by: Bjad K. Almutairy, et al.
Published: (2021-07-01)

Olmesartan medoxomil-loaded mixed micelles: Preparation, characterization and in-vitro evaluation
by: Mohamed A. El-Gendy, et al.
Published: (2017-12-01)

ANTIHYPERTENSIVE EFFICACY OF OLMESARTAN MEDOXOMIL, A NEW ANGIOTENSIN II RECEPTOR ANTAGONIST, AS ASSESSED BY AMBULATORY BLOOD PRESSURE MEASUREMENTS
by: J. M. Neutel, et al.
Published: (2011-04-01)

A review of olmesartan medoxomil monotherapy: antihypertensive efficacy similar to that of other angiotensin II receptor blocker/hydrochlorothiazide combinations?
by: M. Greathouse
Published: (2011-10-01)

Development of Transdermal Oleogel Containing Olmesartan Medoxomil: Statistical Optimization and Pharmacological Evaluation
by: Rania Moataz El-Dahmy, et al.
Published: (2023-03-01)

Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil
by: R. P. Mason
Published: (2012-06-01)

Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil
by: Mason
Published: (2011-06-01)

Stability-indicating comparative methods using mekc and lc for determination of olmesartan medoxomil
by: Lisiane Bajerski, et al.
Published: (2013-01-01)

Stability-indicating comparative methods using mekc and lc for determination of olmesartan medoxomil
by: Lisiane Bajerski, et al.
Published: (2013-01-01)

Efficacy in angiotensin receptor blockade: a comparative review of data with olmesartan
by: Josep Redon, et al.
Published: (2009-09-01)

Development and validation of stability-indicating RP-HPLC method for determination of Olmesartan medoxomile in pharmaceutical dosage form and identification, characterization of alkaline degradation impurity of Olmesartan medoxomile drug substance as well as drug product
by: Jain P.S., et al.
Published: (2012-01-01)

Interaction and Compatibility Studies in the Development of Olmesartan Medoxomil and Hydrochlorothiazide Formulations under a Real Manufacturing Process
by: Mac Arturo Murillo-Fernández, et al.
Published: (2022-02-01)

Blood pressure goal achievement with olmesartan medoxomil-based treatment: additional analysis of the OLMEBEST study
by: Vivencio Barrios, et al.
Published: (2009-08-01)

Critical appraisal of amlodipine and olmesartan medoxomil fixed-dose combination in achieving blood pressure goals
by: Jan Basile
Published: (2010-06-01)

How to deal with the occurrence of rare drug-induced adverse events: the example of sprue-like enteropathy induced by olmesartan medoxomil and other angiotensin-receptor blockers
by: Michel Burnier, et al.
Published: (2020-03-01)

Safety and tolerability of fixed antihypertensive combinations in blood pressure control: focus on olmesartan medoxomil and amlodipine combination
by: Ijlal Uddin, et al.
Published: (2010-11-01)

A novel nano-formulation of olmesartan medoxomil with improved delivery and efficacy in the treatment of indomethacin-induced duodenitis in rats
by: H.A. Murad, et al.
Published: (2023-05-01)

ANTIHYPERTENSIVE EFFICACY AND SAFETY OF OLMESARTAN MEDOXOMIL AND RAMIPRIL IN ELDERLY PATIENTS WITH MILD TO MODERATE ESSENTIAL HYPERTENSION: THE ESPORT STUDY
by: E. Malacco, et al.
Published: (2012-02-01)

Effects of α lipoic acid combined with olmesartan medoxomil on blood glucose and oxidation indicators in patients with diabetic nephropathy
by: Shengfu Jiao, MB, et al.
Published: (2022-04-01)

Integrated Quality by Design Approach for Developing Nanolipidic Drug Delivery Systems of Olmesartan Medoxomil with Enhanced Antihypertensive Action
by: Jagdish Kumar Arun, et al.
Published: (2020-05-01)

High throughput microwell spectrophotometric assay for olmesartan medoxomil in tablets based on its charge-transfer reaction with DDQ
by: Darwish Ibrahim A., et al.
Published: (2014-03-01)

ROLE OF BLOOD PRESSURE REDUCTION IN PREVENTION OF CARDIAC AND VASCULAR HYPERTROPHY
by: H. Yokoyama, et al.
Published: (2011-08-01)

Combined treatment with olmesartan medoxomil and amlodipine besylate attenuates atherosclerotic lesion progression in a model of advanced atherosclerosis
by: Sievers P, et al.
Published: (2015-07-01)

Role of olmesartan in combination therapy in blood pressure control and vascular function
by: Carlos M Ferrario, et al.
Published: (2010-08-01)

Angiotensin II receptor blockade and ventricular remodelling
by: Nagesh S Anavekar, et al.
Published: (2005-03-01)

Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals
by: Hans R. Brunner, et al.
Published: (2011-06-01)

Tratamento da hipertensão arterial com olmesartana medoxomila em escalonamento Based treatment algorithm for essencial hypertension with olmesartan medoxomil
by: Marco Antônio Mota Gomes, et al.
Published: (2008-09-01)

Review: ACE inhibition or angiotensin receptor blockade: which should we use in diabetic patients?
by: Luis M Ruilope, et al.
Published: (2003-06-01)

Novel Solid Self-Nanoemulsifying Drug Delivery System (S-SNEDDS) for Oral Delivery of Olmesartan Medoxomil: Design, Formulation, Pharmacokinetic and Bioavailability Evaluation
by: Ali Nasr, et al.
Published: (2016-06-01)

ANGIOTENSIN II RECEPTOR ANTAGONISTS AND NEPHROPROTECTION: PLACE OF OLMESARTAN
by: V. V. Fomin
Published: (2013-08-01)

Cleaning validation for residual estimation of olmesartan medoxomil on stainless steel surface of pharmaceutical manufacturing equipments using swab sampling and HPLC-DAD method
by: Nitin Dubey, et al.
Published: (2013-06-01)